SynCardia Facebook SynCardia Twitter SynCardia LInkedIn SynCardia Google Plus SynCardia Youtube

SynCardia Systems, Inc.

Press Release:

Russia Transplants 1st Total Artificial Heart Patient after 238 Days

60-Year-Old Grandmother Enjoys 6 Months of Life at Home with New Grandson Using Freedom® Portable Driver to Power Her Total Artificial Heart

Russian Total Artificial Heart recipient Tatyana post-transplant with her surgeon Prof. Leo Bockeria, Head & Chairman of the Bakoulev Scientific Center for Cardiovascular Surgery in Moscow. Russian Total Artificial Heart recipient Tatyana post-transplant with her surgeon Prof. Leo Bockeria, Head & Chairman of the Bakoulev Scientific Center for Cardiovascular Surgery in Moscow. TUCSON, Ariz. – May 24, 2011 – SynCardia Systems, Inc., manufacturer of the SynCardia temporary Total Artificial Heart, announced today that the Bakoulev Scientific Center for Cardiovascular Surgery (BSCCS) in Moscow successfully bridged Russia's first Total Artificial Heart patient to transplant after 238 days of support.

"The Total Artificial Heart is leading edge technology," said Prof. Leo Bockeria, Head and Chairman of the BSCCS, who performed the Total Artificial heart implant. "Fourteen months ago, Tatyana could not walk for more than two minutes. Today, she is doing superb."

Prior to receiving SynCardia's Total Artificial Heart, 60-year-old Tatyana had been suffering from dilated cardiomyopathy for more than three years. Walking more than 30 feet left her gasping for breath. Eventually, she was unable to eat or sleep.  

"We selected Tatyana as our first patient to receive the Total Artificial Heart as a bridge to transplant because without it, she would've had less than two weeks to live," said Dr. Konstantin Shatalov, who assisted Prof. Bockeria during the implant surgery.

Tatyana was implanted with SynCardia's Total Artificial Heart on March 23, 2010. Less than two weeks later, she was able to visit her new grandson at a local maternity hospital. In May 2010, once Tatyana's condition had stabilized, she was switched to the 13.5-lb Freedom® portable driver and discharged from the hospital. After enjoying 180 days of life at home with the Freedom driver, Tatyana returned to the hospital to receive her matching donor heart.

The Freedom portable driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S. SynCardia recognizes and thanks Sergey Sugrobov and DIATECH, the Russian distributor for the Total Artificial Heart, for their commitment and on-going support of the BSCCS.

###

About SynCardia Systems, LLC
SynCardia Systems, LLC in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart is used as a bridge to transplant, helping them survive until a matching donor heart becomes available. SynCardia also manufactures the Freedom® portable driver, which powers the temporary Total Artificial Heart and allows clinically stable patients to be discharged from the hospital to enjoy life at home while they wait for a heart transplant.

Follow SynCardia: Facebook | Twitter | LinkedIn | Google+

SynCardia Contact:
Janelle Drumwright, jdrumwright@syncardia.com, (520) 547-7463

Search offcanvas